Key insights
- Baxter International updated its executive severance plan and amended its bylaws, increasing shares reserved for issuance by 20 million. The new severance plan expands qualifying terminations and establishes tiered benefits. While analysts forecast a return to profitability, the stock is down 43% over the past year. Overall, the changes signal internal adjustments but have a slightly negative influence on the US market due to potential dilution.
Baxter International Inc. (NYSE:BAX) announced several changes to its executive compensation and corporate governance following its 2026 annual meeting of stockholders, according to a press release statement based on a recent SEC filing.The changes come as the healthcare equipment company trades at $17.99, down 43% over the past year, though InvestingPro analysis suggests the stock is undervalued relative to its Fair Value. Despite recent losses, analysts forecast a return to profitability this year with earnings of $1.93 per share.
On Monday, the company’s Compensation and Human Capital Committee approved a new Executive Severance and Change in Control Plan, replacing its prior severance plan. The new plan covers employees at the vice president level and above, including the Interim Chief Financial Officer, Chief Accounting Officer and Controller Anita Zielinski, and all currently employed named executive officers except Chief Executive Officer Andrew Hider. Mr. Hider’s severance terms were separately amended to increase the lump-sum cash payment for employer medical, dental, or vision coverage in certain termination cases from 18 to 24 months.
The updated severance plan maintains existing non-change-in-control severance benefits but expands qualifying terminations to include resignations for "good reason" and terminations due to reduction-in-force or restructuring. It also establishes a tiered structure of severance benefits, with enhanced provisions for terminations within 24 months following a change in control. Executives are required to sign a release of claims and comply with restrictive covenants to receive benefits. There are no excise tax gross-ups under the new plan.
At the annual meeting held Tuesday, stockholders approved the Second Amended and Restated 2021 Incentive Plan, increasing the number of shares reserved for issuance by 20 million. InvestingPro subscribers have access to 8 additional ProTips for BAX, plus comprehensive Pro Research Reports covering over 1,400 US equities. Stockholders also approved an amendment to the company’s certificate of incorporation to set the minimum number of directors at seven, with no stated maximum. The board subsequently amended the bylaws to specify that the board will consist of between seven and twelve directors.
All nine director nominees were elected, and PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for 2026. The compensation of named executive officers for 2025 was also approved on an advisory basis.
These actions and related details were disclosed in a SEC Form 8-K filed Friday.
In other recent news, Baxter International Inc. reported better-than-expected financial results for the first quarter of 2026. The company achieved earnings per share of $0.36, surpassing the forecasted $0.32, marking a 12.5% earnings surprise. Baxter’s revenue also exceeded expectations, reaching $2.7 billion, which is 3.05% above predictions. These results indicate investor optimism despite ongoing challenges. Meanwhile, 4D Path announced the first close of a strategic financing round aimed at developing treatment predictive biomarkers for cancer therapy. Additionally, the company appointed Katherine Vega Stultz and Robert J. Hombach to its Board of Directors, with Stultz taking on the role of Board Chair. These developments highlight significant movements within both companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.